1. 1444PA randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Stinchcombe, T E; Janne, P A; Wang, X; Bertino, E M; Weiss, J M; Bazhenova, L; Gu, L; Lau, C J; Paweletz, C P; Jaslowski, A J; Gerstner, G J; Baggstrom, M Q; Graziano, S L; Bearden, J; Vokes, E E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. (9th January 2018) Authors: Guibert, N; Hu, Y; Feeney, N; Kuang, Y; Plagnol, V; Jones, G; Howarth, K; Beeler, J F; Paweletz, C P; Oxnard, G R Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 1049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. (13th July 2018) Authors: Hanna, G J; Supplee, J G; Kuang, Y; Mahmood, U; Lau, C J; Haddad, R I; Jänne, P A; Paweletz, C P Journal: Annals of oncology Issue: Volume 29:Number 9(2018) Page Start: 1980 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (20th March 2019) Authors: Li, B T; Janku, F; Jung, B; Hou, C; Madwani, K; Alden, R; Razavi, P; Reis-Filho, J S; Shen, R; Isbell, J M; Blocker, A W; Eattock, N; Gnerre, S; Satya, R V; Xu, H; Zhao, C; Hall, M P; Hu, Y; Sehnert, A J; Brown, D Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 597 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗